Pembrolizumab improves survival in early-stage resectable lung cancer

Pembrolizumab as neoadjuvant and adjuvant therapy significantly extended OS among adults with resectable stage II, IIIA or IIIB non-small cell lung cancer, according to the agent’s manufacturer.
A second prespecified interim analysis from the randomized phase 3 KEYNOTE-671 trial showed no new safety issues associated with neoadjuvant and adjuvant use of pembrolizumab (Keytruda, Merck) — a PD-1 inhibitor previously approved for multiple NSCLC indications.
“This is a significant milestone in the treatment of resectable non-small cell lung cancer, as it represents the first phase

Pembrolizumab as neoadjuvant and adjuvant therapy significantly extended OS among adults with resectable stage II, IIIA or IIIB non-small cell lung cancer, according to the agent’s manufacturer.
A second prespecified interim analysis from the randomized phase 3 KEYNOTE-671 trial showed no new safety issues associated with neoadjuvant and adjuvant use of pembrolizumab (Keytruda, Merck) — a PD-1 inhibitor previously approved for multiple NSCLC indications.
“This is a significant milestone in the treatment of resectable non-small cell lung cancer, as it represents the first phase